SEARCH

SEARCH BY CITATION

References

  • 1
    Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G, Einsele H, Gaspar HB, Gratwohl A, Passweg J, Peters C, Rocha V, Saccardi R, Schouten H, Sureda A, Tichelli A, Velardi A, Niederwieser D. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010;45:219-234.
  • 2
    Shenoy S. Hematopoietic stem cell transplantation for sickle cell disease: current practice and emerging trends. Hematology Am Soc Hematol Educ Program 2011;2011:273-279.
  • 3
    Sodani P, Gaziev D, Polchi P, Erer B, Giardini C, Angelucci E, Baronciani D, Andreani M, Manna M, Nesci S, Lucarelli B, Clift RA, Lucarelli G. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood 2004;104:1201-1203.
  • 4
    Sodani P, Isgro A, Gaziev J, Polchi P, Paciaroni K, Marziali M, Simone MD, Roveda A, Montuoro A, Alfieri C, De Angelis G, Gallucci C, Erer B, Isacchi G, Zinno F, Adorno G, Lanti A, Faulkner L, Testi M, Andreani M, Lucarelli G. Purified T-depleted, CD34+ peripheral blood and bone marrow cell transplantation from haploidentical mother to child with thalassemia. Blood 2010;115:1296-1302.
  • 5
    Bohgaki T, Atsumi T, Koike T. Multiple autoimmune diseases after autologous stem-cell transplantation. N Engl J Med 2007;357:2734-2736.
  • 6
    Gajjar A, Pizer B. Role of high-dose chemotherapy for recurrent medulloblastoma and other CNS primitive neuroectodermal tumors. Pediatr Blood Cancer 2010;54:649-651.
  • 7
    Bregni M, Herr W, Blaise D; Solid Tumor Working Party of EBMT. Allogeneic stem cell transplantation for renal cell carcinoma. Expert Rev Anticancer Ther 2011;11:901-911.
  • 8
    Baldomero H, Gratwohl M, Gratwohl A, Tichelli A, Niederwieser D, Madrigal A, Frauendorfer K; European Group for Blood and Marrow Transplantation EBMT. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant 2011;46:485-501.
  • 9
    Bensinger WI. Allogeneic transplantation: peripheral blood vs. bone marrow. Curr Opin Oncol 2012;24:191-196.
  • 10
    Olavarria E, Kanfer EJ. Selection and use of chemotherapy with hematopoietic growth factors for mobilization of peripheral blood progenitor cells. Curr Opin Hematol 2000;7:191-196.
  • 11
    Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, Gooley T, Demirer T, Schiffman K, Weaver C. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995;13:2547-2555.
  • 12
    Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995;86:3961-3969.
  • 13
    Alegre A, Tomas JF, Martinez-Chamorro C, Gil-Fernandez JJ, Fernandez-Villalta MJ, Arranz R, Diaz MA, Granda A, Bernardo MR, Escudero A, Lopez-Lorenzo JL, Fernandez-Ranada JM. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs. G-CSF alone. Bone Marrow Transplant 1997;20:211-217.
  • 14
    Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Keating C, O'Connor C, Berkman E, Erban JK, Sprague KA, Miller KB, Schenkein DP. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001;98:2059-2064.
  • 15
    Rhodes B, Anderlini P. Allogeneic peripheral blood stem cell collection as of 2008. Transfus Apher Sci 2008;38:219-227.
  • 16
    Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009;43:181-195.
  • 17
    Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS, Smith AL, DiPersio JF. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008;14:1045-1056.
  • 18
    Jantunen E, Lemoli RM. Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept. Transfusion 2012;52:906-914.
  • 19
    Lemoli RM, Tafuri A, Fortuna A, Petrucci MT, Ricciardi MR, Catani L, Rondelli D, Fogli M, Leopardi G, Ariola C, Tura S. Cycling status of CD34+ cells mobilized into peripheral blood of healthy donors by recombinant human granulocyte colony-stimulating factor. Blood 1997;89:1189-1196.
  • 20
    Lysak D, Koza VR, Jindra P. Factors affecting PBSC mobilization and collection in healthy donors. Transfus Apher Sci 2005;33:275-283.
  • 21
    Zhang C, Chen XH, Zhang X, Gao L, Gao L, Kong PY, Peng XG, Sun AH, Gong Y, Zeng DF, Wang QY. Stem cell collection in unmanipulated HLA-haploidentical/mismatched related transplantation with combined granulocyte-colony stimulating factor-mobilised blood and bone marrow for patients with haematologic malignancies: the impact of donor characteristics and procedural settings. Transfus Med 2010;20:169-177.
  • 22
    Suzuya H, Watanabe T, Nakagawa R, Watanabe H, Okamoto Y, Onishi T, Abe T, Kawano Y, Kagami S, Takaue Y. Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors. Vox Sang 2005;89:229-235.
  • 23
    Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery 1962;51:224-232.
  • 24
    World Health Organization. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series 854. Geneva: World Health Organization; 1995.
  • 25
    Robinson JD, Lupkiewicz SM, Palenik L, Lopez LM, Ariet M. Determination of ideal body weight for drug dosage calculations. Am J Hosp Pharm 1983;40:1016-1019.
  • 26
    Elliott C, Samson DM, Armitage S, Lyttelton MP, McGuigan D, Hargreaves R, Giles C, Abrahamson G, Abboudi Z, Brennan M, Kanfer EJ. When to harvest peripheral-blood stem cells after mobilization therapy: prediction of CD34-positive cell yield by preceding day CD34-positive concentration in peripheral blood. J Clin Oncol 1996;14:970-973.
  • 27
    Lane TA, Bashey A, Carrier E, Holman P, Castro J, Mullen M, Ward DM, Ada O, Ball ED. Improving the efficiency of PBPC collection by pre-apheresis peripheral blood and mid-apheresis product measurements of CD34 cells. Cytotherapy 2004;6:318-327.
  • 28
    Grigg AP, Roberts AW, Raunow H, Houghton S, Layton JE, Boyd AW, McGrath KM, Maher D. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995;86:4437-4445.
  • 29
    Nakamura R, Auayporn N, Smith DD, Palmer J, Sun JY, Schriber J, Pullarkat V, Parker P, Rodriguez R, Stein A, Rosenthal J, Wang S, Karanas C, Gaal K, Senitzer D, Forman SJ. Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates. Biol Blood Marrow Transplant 2008;14:449-457.
  • 30
    Pulsipher MA, Chitphakdithai P, Logan BR, Leitman SF, Anderlini P, Klein JP, Horowitz MM, Miller JP, King RJ, Confer DL. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood 2009;114:2606-2616.
  • 31
    Wang TF, Wen SH, Chen RL, Lu CJ, Zheng YJ, Yang SH, Chu SC, Kao RH, Chen SH. Factors associated with peripheral blood stem cell yield in volunteer donors mobilized with granulocyte colony-stimulating factors: the impact of donor characteristics and procedural settings. Biol Blood Marrow Transplant 2008;14:1305-1311.
  • 32
    Dubrovsky L, Wong EC, Perez-Albuerne E, Loechelt B, Kamani N, Sande J, Mintz K, Paul W, Luban NL, Rood BR, Fry T. CD34(+) collection efficiency as a function of blood volumes processed in pediatric autologous peripheral blood stem cell collection. J Clin Apher 2011;26:131-137.
  • 33
    Vasu S, Leitman SF, Tisdale JF, Hsieh MM, Childs RW, Barrett AJ, Fowler DH, Bishop MR, Kang EM, Malech HL, Dunbar CE, Khuu HM, Wesley R, Yau YY, Bolan CD. Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood 2008;112:2092-2100.
  • 34
    Blogowski W, Ratajczak MZ, Zyzniewska-Banaszak E, Dolegowska B, Starzynska T. Adipose tissue as a potential source of hematopoietic stem/progenitor cells. Obesity (Silver Spring) 2012;20:923-931.
  • 35
    Kroger N, Renges H, Sonnenberg S, Kruger W, Gutensohn K, Dielschneider T, Cortes-Dericks L, Zander AR. Stem cell mobilisation with 16 microg/kg vs. 10 microg/kg of G-CSF for allogeneic transplantation in healthy donors. Bone Marrow Transplant 2002;29:727-730.